Home | My NASDAQ | Tools | Mobile | Company List | ETFs | Pre-Market Quotes Real-Time Quotes After Hours Quotes
Home > Quotes > AGEN
Save my stocks for next time

Symbol List ViewsSymbol List Views

Stock DetailsStock Details

Stock DetailsCHARTS

Stock DetailsCOMPANY NEWS

Stock DetailsSTOCK ANALYSIS

Stock DetailsFUNDAMENTALS

Stock DetailsHOLDINGS

Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.


Don't know the stock symbol? Use the symbol lookup tool.

Alphabetize the sort order of my symbols 
Symbol Lookup
Last Sale:
Change Net/%:   
Best Bid /Ask: N/A / N/A
1 Year Target: 12.5
Today's High/Low:  / 
Share Volume:
50 Day Avg. Daily Volume This is the average share volume for the past 50 trading days. This field allows you to compare today's trading to the average daily volume. 300,277
Previous Close: $ 5.14
52 Week High /Low: $ 7.41 / $ 1.92
Shares Outstanding "Shares Outstanding" means the total number of shares outstanding of the NASDAQ-listed security only. Issues not listed on NASDAQ, or securities convertible into the NASDAQ-listed security, are not included in the shares outstanding amount. In the case of a company with American Depositary Receipts (“ADRs”), “shares outstanding” means the total number of outstanding shares in the class of security underlying the ADR adjusted by the ADS ratio. "Shares outstanding" excludes treasury shares and is based on the information reported in the company's most recent periodic SEC filing or other communication with NASDAQ, adjusted for corporate actions such as stock dividends and splits. Use and display of a newly reported value may be briefly delayed pending review for accuracy or to facilitate the management of indices. 21,455,000
Market Value "Market Value of Listed Security" means the market value of the NASDAQ-listed security only and is calculated using the current market price per share of the security multiplied by the number of shares outstanding. Issues not listed on NASDAQ, or securities convertible into the NASDAQ-listed security, are not included in the market value of listed security calculation. In the case of American Depositary Receipts (“ADRs”), “Market Value of Listed Security” is calculated using the total number of outstanding shares in the class of security underlying the NASDAQ-listed ADR adjusted by the ADS ratio. $ 111,566,000
P/E Ratio: NE
Forward P/E(1y) A widely used stock evaluation measure. For a security, the Price/Earnings Ratio is given by dividing the Last Sale Price by the Average EPS (Earnings Per Share) Estimate for the specified fiscal time period. The forward P/E refers to the value for the next full year. NE
Earnings Per Share (EPS) The EPS listed on our infoquote and Summary Quote page is "12-mos Rolling". EPS represents the portion of a company's profit allocated to each outstanding share of common stock. Net income (reported or estimated) for a period of time is divided by the total number of shares outstanding (TSO) during that period; See growth rate measures for EPS. Our vendor's methodology for the EPS on the infoquote and Summary Quote pages follows the EPS used by the majority of the analysts following the stock, in many cases this is EBITDA EPS. $ -0.58
Annualized dividend N/A
Ex Dividend Date N/A
Dividend Payment Date N/A
Current Yield 0 %
Special Dividend Date N/A
Special Dividend Payment Date N/A
Beta 0.67
NASDAQ Official Open Price NASDAQ Official Opening Price: This process identifies the NASDAQ-specific opening prices for NASDAQ-listed issues. $ 5.10
Date of Open Price This field refers to the date the NASDAQ Official Open Price was disseminated for a given stock. It is possible that the date will not be from the current trading day; this indicates that the stock didn't trade on NASDAQ during the current trading day. The NASDAQ Official Open Price is updated only when the stock is traded on NASDAQ. May 25, 2012
NASDAQ Official Close Price The NASDAQ® Official Closing Price (NOCP) is a process for identifying the NASDAQ market-specific closing price for NASDAQ-listed issues. The NOCP replaces the NASDAQ market-specific closing price that was based solely on the last reported NASDAQ trade. Subject to review by NASDAQ MarketWatch, the NOCP will equal the normalized price of the last trade reported to NASDAQ’s proprietary trade reporting system—Automated Confirmation Transaction ServiceSM (ACTSM—with a last sale eligible sale condition modifier as of 4:00:02 p.m., US Eastern Time. "Normalizing" the NOCP means it will be adjusted to the nearest prevailing inside quote whenever the last sale is reported away from the inside market. Market participants, data distributors and investors will be provided with the NOCP for all NASDAQ Global Select MarketSM, NASDAQ Global MarketSM and NASDAQ Capital MarketSM securities. $ 5.20
Date of Close Price This field refers to the date the NOCP was disseminated for a given stock. It is possible that the date will not be from the prior day; this indicates that the stock didn't trade on NASDAQ on the prior day. The NOCP is updated only when the stock is traded on NASDAQ. May 25, 2012
Community Sentiment

 Intraday Chart

5d | 1m | 6m | 12m | More Charting

 Company Description (as filed with the SEC)

Agenus Inc., including its subsidiaries, referred to in this Annual Report on Form 10-K as “Agenus,” the “Company,” “we,” “us,” and “our,” is a biotechnology company focused on the development and commercialization of technologies to treat cancers and infectious diseases. Our core technology portfolio consists of our Saponin Platform (based on our saponin adjuvant based technologies) and our Heat Shock Protein (“HSP”) Platform (based on our HSP based technologies). Some of our key candidates from these technology platforms are highlighted below: • QS-21 Stimulon® adjuvant (“QS-21”): QS-21, from our Saponin Platform, is an adjuvant, or a substance added to a vaccine or other immunotherapy that is intended to enhance immune response. The key licensees of QS-21 are GlaxoSmithKline (“GSK”) and JANSSEN Alzheimer Immunotherapy (“JANSSEN AI”).  ... More ...  






Company News and Commentary for AGEN Subscribe


Zacks #1 Rank Additions for Thursday - Tale of the Tape
5/17/2012 9:10:06 AM - Zacks.com
Zacks #1 Rank Additions for Monday - Tale of the Tape
5/14/2012 9:09:09 AM - Zacks.com
Agenus Reports First Quarter 2012 Financial Results and Corporate Updates
4/25/2012 7:00:00 AM - GlobeNewswire
New Phase 2 Data From Brain Cancer Study With Agenus' Prophage Vaccine (HSPPC-96) Presented at Plenary Session of AANS
4/17/2012 10:30:00 AM - GlobeNewswire
Mentor Capital Cancer Immunotherapy Index Gains 47% During First Quarter
4/17/2012 10:22:00 AM - Business Wire
Agenus' Brain Cancer Vaccine Phase 2 Study to be Presented at Plenary Session of the 80th American Association of Neurological Surgeons (AANS) Annual Scientific Meeting
4/2/2012 7:00:00 AM - GlobeNewswire
Agenus Inc. (AGEN) Rose To Over A 9-Month High
3/20/2012 7:53:00 AM - RTT News

Read more AGEN News & Commentary
 

Consensus Recommendation

Analyst Info
Annual EPS Est: $-1.21
Quarterly EPS Est: -0.26
PEG Ratio: -.01
Mean Recommendation:
View Summary/View All 		1

Data is provided by Zacks Investment Research